CA2318664A1 - Systemes d'expression nucleotidiques a immunogenicite reduite destines a la therapie genique - Google Patents

Systemes d'expression nucleotidiques a immunogenicite reduite destines a la therapie genique Download PDF

Info

Publication number
CA2318664A1
CA2318664A1 CA002318664A CA2318664A CA2318664A1 CA 2318664 A1 CA2318664 A1 CA 2318664A1 CA 002318664 A CA002318664 A CA 002318664A CA 2318664 A CA2318664 A CA 2318664A CA 2318664 A1 CA2318664 A1 CA 2318664A1
Authority
CA
Canada
Prior art keywords
gene
vector
virus
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002318664A
Other languages
English (en)
Inventor
Thomas J. Radosevich
Charles J. Link, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Gene Therapy Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2318664A1 publication Critical patent/CA2318664A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé permettant la suppression de la réponse immunitaire en cas d'introduction de gènes selon des techniques de type virales ou non virales. A cet effet, on incorpore des gènes d'immuno-dépression dans le système d'introduction des gènes. Ces gènes d'immuno-dépression peuvent s'utiliser en complément d'un traitement thérapeutique ou directement comme traitement thérapeutique.
CA002318664A 1998-01-14 1999-01-13 Systemes d'expression nucleotidiques a immunogenicite reduite destines a la therapie genique Abandoned CA2318664A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7140998P 1998-01-14 1998-01-14
US60/071,409 1998-01-14
PCT/US1999/000733 WO1999036562A1 (fr) 1998-01-14 1999-01-13 Systemes d'expression nucleotidiques a immunogenicite reduite destines a la therapie genique

Publications (1)

Publication Number Publication Date
CA2318664A1 true CA2318664A1 (fr) 1999-07-22

Family

ID=22101129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002318664A Abandoned CA2318664A1 (fr) 1998-01-14 1999-01-13 Systemes d'expression nucleotidiques a immunogenicite reduite destines a la therapie genique

Country Status (5)

Country Link
EP (1) EP1045920A1 (fr)
JP (1) JP2002508976A (fr)
AU (1) AU2114899A (fr)
CA (1) CA2318664A1 (fr)
WO (1) WO1999036562A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019195B4 (de) * 2000-04-17 2006-03-09 Heart Biosystems Gmbh Reversible Immortalisierung
AUPQ811700A0 (en) * 2000-06-13 2000-07-06 Crc Pest Animal Control Biological control agent
CA2420944A1 (fr) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition de l'infection par cmv et de la dissemination de ce dernier
WO2002062296A2 (fr) 2001-02-02 2002-08-15 Chemocentryx, Inc. Procedes et compositions utiles dans la stimulation d'une reponse immunitaire
AU2019239562A1 (en) * 2018-03-19 2020-08-13 Boehringer Ingelheim Vetmedica Gmbh New EHV with inactivated UL18 and/or UL8

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750398A (en) * 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
US5846806A (en) * 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
JPH11503024A (ja) * 1995-04-04 1999-03-23 セル・ジェネシス・インコーポレイテッド 細胞表面のクラスｉ ｍｈｃタンパク質の低レベルを有する遺伝子学的に修飾された細胞の移植
US5891857A (en) * 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins

Also Published As

Publication number Publication date
WO1999036562A1 (fr) 1999-07-22
AU2114899A (en) 1999-08-02
WO1999036562A9 (fr) 1999-09-30
EP1045920A1 (fr) 2000-10-25
JP2002508976A (ja) 2002-03-26

Similar Documents

Publication Publication Date Title
KR102319845B1 (ko) 조류 숙주 세포에 대한 crispr-cas 시스템
AU2018229561B2 (en) Recombinant adenoviruses and use thereof
CN108138154B (zh) 用于治疗黏多糖贮积病的腺相关病毒载体
CN111295449B (zh) 腺病毒载体及其用途
ES2388527T3 (es) Vacunas de VIH basadas en Env de múltiples clados de VIH
CA2776272C (fr) Mise au point d'un vaccin preventif contre l'infection par filovirus chez les primates
AU2016317936A1 (en) Recombinant vectors comprising 2A peptide
KR102494564B1 (ko) 말라리아 백신
US20220056475A1 (en) Recombinant poxviruses for cancer immunotherapy
KR20110039258A (ko) 개선된 단백질 발현계
CN112534047A (zh) 经修饰的t细胞及其用途
CN113396222A (zh) 腺相关病毒(aav)生产细胞系和相关方法
KR20210105382A (ko) 단백질을 코딩하는 rna
KR20220121844A (ko) 유전자의 발현을 동시에 조절하기 위한 조성물 및 방법
KR20220084282A (ko) Ipsc로부터의 피질 신경 전구 세포
JP2024037917A (ja) 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法
CN115927299A (zh) 增加双链rna产生的方法和组合物
KR20200083510A (ko) 아데노바이러스 및 이의 용도
CN114026242A (zh) 具有髓鞘蛋白零启动子的aav载体及其用于治疗雪旺细胞相关疾病如charcot-marie-tooth疾病的用途
KR102055215B1 (ko) 돼지 써코바이러스 2형 캡시드 단백질 및 이를 포함하는 약학적 조성물의 제조 방법
JP2024037797A (ja) がんを処置するための感染性核酸の使用
CA2318664A1 (fr) Systemes d'expression nucleotidiques a immunogenicite reduite destines a la therapie genique
KR20240021906A (ko) 발현 벡터, 박테리아 서열-무함유 벡터, 및 이를 제조하고 사용하는 방법
TW202309288A (zh) 調節基因表現之組合物及方法
CN113677800A (zh) 包含用于结合结构域和可分泌肽的基因的重组载体

Legal Events

Date Code Title Description
FZDE Dead